Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (301-310 of 418) with videos related to

Pageof 42
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Final version of 2009 AJCC melanoma staging and classificationCharles M Balch, Jeffrey E Gershenwald, Seng-Jaw Soong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol HApril K S Salama, Shuli Li, Erin R Macrae, et al.
Nature|November 25, 2011
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Poulikos I Poulikakos, Yogindra Persaud, Manickam Janakiraman, et al.
Molecular Cancer Therapeutics|October 17, 2014
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanomaDavid J Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, et al.
Pigment Cell & Melanoma Research|November 20, 2014
Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cellsMarie R Webster, Mai Xu, Kathryn A Kinzler, et al.
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.
Science Signaling|December 25, 2014
Systematic identification of signaling pathways with potential to confer anticancer drug resistanceColin A Martz, Kathleen A Ottina, Katherine R Singleton, et al.
JAMA Oncology|December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized TrialKevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaDirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.
JCO Precision Oncology|January 14, 2026
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i><sup><i>V600E</i></sup> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol HApril K S Salama, Victoria Wang, Erin R Macrae, et al.
Pageof 42

Showing results (301-310 of 418) with videos related to

Sort By:
Pageof 42
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Final version of 2009 AJCC melanoma staging and classificationCharles M Balch, Jeffrey E Gershenwald, Seng-Jaw Soong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol HApril K S Salama, Shuli Li, Erin R Macrae, et al.
Nature|November 25, 2011
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Poulikos I Poulikakos, Yogindra Persaud, Manickam Janakiraman, et al.
Molecular Cancer Therapeutics|October 17, 2014
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanomaDavid J Panka, Elizabeth Buchbinder, Anita Giobbie-Hurder, et al.
Pigment Cell & Melanoma Research|November 20, 2014
Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cellsMarie R Webster, Mai Xu, Kathryn A Kinzler, et al.
The Oncologist|May 30, 2013
Ipilimumab for patients with advanced mucosal melanomaMichael A Postow, Jason J Luke, Mark J Bluth, et al.
Science Signaling|December 25, 2014
Systematic identification of signaling pathways with potential to confer anticancer drug resistanceColin A Martz, Kathleen A Ottina, Katherine R Singleton, et al.
JAMA Oncology|December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized TrialKevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaDirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.
JCO Precision Oncology|January 14, 2026
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i><sup><i>V600E</i></sup> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol HApril K S Salama, Victoria Wang, Erin R Macrae, et al.
Pageof 42